Compare PSNY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNY | IMCR |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Sweden | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2021 | 2016 |
| Metric | PSNY | IMCR |
|---|---|---|
| Price | $13.83 | $33.95 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $15.00 | ★ $66.33 |
| AVG Volume (30 Days) | 124.7K | ★ 456.6K |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $31.06 | $14.57 |
| Revenue Next Year | $47.98 | $8.21 |
| P/E Ratio | ★ N/A | $148.70 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $0.50 | $27.56 |
| 52 Week High | $23.75 | $40.71 |
| Indicator | PSNY | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 54.20 |
| Support Level | $12.36 | $30.95 |
| Resistance Level | $15.01 | $35.73 |
| Average True Range (ATR) | 0.78 | 1.32 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 41.59 | 53.52 |
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.